Oxford BioMedica plc

BETOVAC

clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing lipsome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations containing nucleic acids for use in the treatment of viral and bacterial infections, cancer, HIV and aids related infections and bodily conditions associated with impaired immunosystems; pharmaceutical preparations in the field of gene therapy, pharmaceutical preparations for the treatment of cancer;chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations;instruments and apparatus for the administration of gene therapy, namely, syringes, scalpels, catheters, tubes for the administration of gene therapy, except for containers for receiving of a patient's blood;

BETOVAC

Clinical medical reagents for use in gene therapy; pharmaceutical preparations, namely, vaccines, for use in gene therapy; therapeutic compositions containing lipsome reagents or nucleic acid suitable for gene therapy; pharmaceutical preparations containing nucleic acids for use in the treatment of viral and bacterial infections, cancer, HIV and aids related infections and bodily conditions associated with impaired immunosystems, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation, diseases of the nervous system, cardiac disorders, inflammatory and auto-immune diseases; pharmaceutical preparations, namely, vaccines, for use in the treatment of cancer, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation, diseases of the nervous system, cardiac disorders, inflammatory and auto-immune diseases; enzymes and enzyme preparations for medical purposes; retroviral vector and retroviral vector manufacturing preparations; chemotherapeutics for medical use;Instruments and apparatus for the administration of gene therapy products, namely, Pre-filled vials, syringes and injectors, catheters, and tubes; surgical and medical apparatus and instruments, namely, scalpels, knives, forceps and surgical clips;

BIOMEDICA

Gene therapy products for medical use, namely, clinical medical reagents, liposome reagents, nucleic acids, and vaccines for use in gene therapy, gene-based medicines, chemotherapeutics, and pharmaceutical preparations for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, bodily conditions associated with impaired immunosystems, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation, diseases of the nervous system, neuro-degenerative disorders, cardiac disorders, cystic fibrosis, inflammatory and auto-immune diseases; enzymes and enzyme preparations for medical purposes for use in gene delivery technologies; retroviral vector manufacturing preparations and retroviral vector preparations for medical use for gene delivery technologies; chemical products for medical use for genetic engineering and in gene therapy; none of the foregoing goods including or for use in connection with immunoassay diagnostic test devices containing reagent test strips for detecting the presence of drugs of abuse in saliva or urine specimens;BIO MEDICA;Chemical products for use in industry and science for use in gene delivery technology and the manufacture of pharmaceuticals and retroviral vector preparations; enzymes for laboratory and research use; chemical products for in vitro use in laboratories and for analysis, namely, for use in gene delivery technology, micro-organisms for laboratory and research use, cell cultures for laboratory and research use, plasmids and cultures of micro-organisms for laboratory and research use, deoxyribonucleic acid sequences for laboratory and research use, cloning vehicles, namely, chemical preparations for scientific purposes for use in biotechnology, research and development and recombinant deoxyribonucleic acid variations thereof for laboratory and research use, all for in vivo use; none of the goods in this class for medical or veterinary purposes; none of the foregoing goods including or for use in connection with the immunoassay diagnostic test devices containing reagent test strips for detecting the presence of drugs of abuse in saliva or urine specimens;Medical services;Instruments and apparatus for the administration of gene therapy products, namely, injection devices, syringes, scalpels, catheters, tubes for the administration of gene therapy products; surgical and medical apparatus and instruments, namely, injection devices, syringes, scalpels, catheters, tubes for medical services, none being blood circulatory apparatus and instruments, blood pumps, flow probes for blood pumps or blood circulatory devices for medical purposes;Scientific and medical research in the fields of genetic engineering and gene therapy and scientific and medical development in the fields of genetic engineering and gene therapy, genetic engineering services and gene therapy and prophylaxis for the development and commercialization of therapeutic vaccines and gene-based therapies, namely, development of new technology for others in the field of biotechnology, collaboration for others with other biomedical and pharmaceutical entities for the commercialization of therapeutic vaccines and gene-based therapies; none of the foregoing services including or for use in connection with the immunoassay diagnostic test devices containing reagent test strips for detecting the presence of drugs of abuse in saliva or urine specimens;

CHANEX

Clinical, medical reagents for use in the gene therapy; pharmaceutical preparations for use in gene therapy; Therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acids for gene therapy; pharmaceutical preparations containing nucleic acid for use in the treatment of cancer, HIV and AIDS related infections and bodily conditions associated with impaired immunosystems; viral and bacterial diseases, cancer and cystic fibrosis, pharmaceutic preparations in the field of gene therapy, pharmaceutics preparations for the treatment of cystic fibrosis;Instruments and apparatus for the administration of gene therapy, namely, syringes, scalpels, catheters, tubes for the administration of gene therapy products; surgical and medical apparatus and instruments, namely, syringes, scalpels, catheters and tubes for medical services;

CHANEX

CLINICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPOSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPUETIC COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACID FOR USE IN THE TREATMENT OF CANCER, HIV AND AIDS-RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS, VIRAL AND BACTIERIAL DISEASES, CANCER AND CYSTIC FIBROSIS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACUETICAL PREPARATIONS FOR THE TREATMENT OF CYSTIC FIBROSIS;INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY, NAMELY, SYRINGES, SCALPELS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS; SURGICAL AND MEDICAL APPARATUS AND INSTRUMENTS, NAMELY, SYRINGES, SCALPELS, CATHETERS AND TUBES FOR MEDICAL SERVICES;genetic engineering services and biotechnology services, namely, development and commercialization of therapeutic vaccines and gene-based therapies in respect of oncology and neurotherapy;

CORECTOGEN

CLINICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING NUCLEIC ACID FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER;CHEMICAL COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS AND RETROVIRAL VECTOR PREPARATIONS;INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY, NAMELY, SYRINGES, SCALPELS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS; SURGICAL AND MEDICAL APPARATUS AND INSTRUMENTS FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS, NAMELY, SYRINGES, SCALPELS, INJECTORS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS;

ECOPACK

Gene therapy products, namely, clinical or medical reagents for use in gene therapy; retroviral vector preparations for clinical or medical laboratory use; chemical and biochemical products for use in medical science, namely, diagnostic reagents for clinical or medical laboratory use; chemical and biochemical products for in vitro use in laboratories; reagents, namely, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for clinical or medical laboratory use, namely, in vivo use;Chemical and biochemical products for use in gene therapy; reagents for use in scientific and medical research concerning gene therapy, namely, enzymes and enzymes for use in the manufacture of gene therapy products, chemical compositions containing nucleic acids for use in the manufacture of retroviral vector preparations;Scientific and medical research and development, medical services; genetic engineering services for others; biotechnology research and development services for others;

ENCORSTAT

In the statement, Page 2, Column 1, line 12,12-9-2009 should be deleted, and 12-3-2009 should be inserted.;Gene therapy products, namely, genetically engineered tissues for transplant purposes and gene delivery pharmaceuticals; vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic / angiogenic molecules, all for medical purposes in connection with the treatment of diseases of the eye; nucleic acid sequences and chemical reagents for medical purposes in connection with the treatment of diseases of the eye, namely, retroviral vectors and retroviral vector manufacturing preparations; pharmaceutical and biochemical preparations for the treatment of diseases of the eye and Usher's disease; biochemical preparations for medical purposes, namely, gene based therapeutics for the treatment of a juvenile degenerative retinal disease; pre-filled vials containing gene therapy pharmaceutical preparations in connection with the treatment of diseases of the eye;ENCORE STAT;Color is not claimed as a feature of the mark.;Enzymes for scientific and research purposes in connection with treatment of the eye; chemicals for use in industry and science, namely, chemicals for in-vitro use and analysis in laboratories in connection with treatment for the eye; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, nucleic acid sequences and chemical reagents for other than medical and veterinary purposes, namely, cloning vehicles and vectors and recombinant deoxyribonucleic acid variations thereof, all for in-vitro and in-vivo use in laboratory or medical research in connection with treatment for the eye; chemical reagents for use in medical science;Medical instruments and apparatus for the administration of antibody-based therapy, gene therapy and prophylaxis preparations and substances in connection with the treatment of diseases of the eye; syringes and injectors for medical purposes in connection with the treatment of diseases of the eye;Scientific and medical research and development in connection with the treatment of diseases of the eye; genetic engineering services, biotechnology services, namely, research and development of new products for others in the field of biotechnology in connection with the treatment of diseases of the eye; advisory services relating to research and development of gene therapy products all in connection with the treatment of diseases of the eye and specifically excluding analysis services;

FUSITAB

Gene therapy and prophylaxis products, namely, clinical, medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents/nucleic acid/antibodies for gene therapy; vaccines; enzymes and enzyme preparations for medical purposes, namely, gene therapy for use in the treatment of viral and bacterial infections, cancer and bodily conditions associated with immunosystems;instruments, apparatus surgical and medical apparatus and instruments, all for the administration of gene therapy treatment and for the administration of prophylaxis products, namely, syringes, scalpels, catheters, and tubes for the administration of gene therapy products;Scientific and medical research and product development; medical services; genetic engineering services; biotechnology services, namely, research and development of new products in the field of biotechnology; scientific and medical research and development of new products in the field of gene therapy;

GLIOSTAT

clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing lipsome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations containing nucleic acids for use in the treatment of viral and bacterial infections, cancer, HIV and aids related infections and bodily conditions associated with impaired immunosystems; pharmaceutical preparations in the field of gene therapy; pharmaceutical preparations for the treatment of cancer;chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations;instruments and apparatus for the administration of gene therapy, namely, syringes, scalpels, catheters, tubes for the administration of gene therapy products; surgical and medical apparatus and instruments for the administration of gene therapy products;

GLIOSTAT

CHEMICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPOSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING NUCLEIC ACID FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER;CHEMICAL COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS AND RETROVIRAL VECTOR PREPARATIONS;

GLIOSTAT

INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY, NAMELY, SYRINGES, SCALPELS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS; SURGICAL AND MEDICAL APPARATUS AND INSTRUMENTS FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS;

HEPXIA

CLINICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPOSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER;CHEMICAL COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE MANUFACTURE OF GENE THERAPY PREPARATIONS;INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY NAMELY, SYRINGES, SCALPELS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS;

HEPXIA

CLINICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPOSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER;CHEMICAL COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE MANUFACTURE OF GENE THERAPY PREPARATIONS;INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY, NAMELY, SYRINGES, SCALPELS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS;SCIENTIFIC AND MEDICAL RESEARCH AND DEVELOPMENT, MEDICAL SERVICES, GENETIC ENGINEERING SERVICES, BIOTECHNOLOGY SERVICES ALL IN RELATION TO THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS;

HI-8

Pharmaceutical preparations for the treatment, relief and/or prevention of cancer and infectious diseases; biological preparations for the treatment, relief and/or prevention of cancer and infectious diseases; vaccines for the treatment, relief and/or prevention of cancer and infectious diseases; veterinary preparations for the treatment, relief and/or prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment, relief and/or prevention of cancer and infectious diseases in pre-filled vials; biological preparations for the treatment, relief and/or prevention of cancer and infectious diseases in pre-filled vials; vaccines for the treatment, relief and/or prevention of cancer and infectious diseases in pre-filled vials; veterinary preparations for the treatment, relief and/or prevention of cancer and infectious diseases in pre-filled vials;HIGH-EIGHT;Medical services; advisory services relating to vaccination regimens; advisory services relating to the treatment, relief and/or prevention of cancer and infectious diseases in humans and animals;Medical apparatus, devices and instruments, namely, hypodermic syringes, injectors for medical purposes, namely, jet injectors, medication injectors, hypodermic injectors, vaccinators; veterinary apparatus, devices and instruments, namely, hypodermic syringes, injectors for medical purposes, namely jet injectors, medication injectors, hypodermic injectors, vaccinators;Scientific research services; consultancy services in the field of scientific research; provision of information relating to scientific research; medical and clinical research and development for others in the field of gene therapy;

IMMSTAT

clinical medical reagents for use in gene therapy pharmaceutical preparations for use in gene therapy; therapeuctic compositions containing lipsome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations containing nucleic acids for use in the treatment of viral and bacterial infections, cancer, HIV and aids related infections and bodily conditions associated with impaired immunosystems; pharmaceutical preparations in the field of gene therapy; pharmaceutical preparations for the treatment of cancer;chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations;instruments and apparatus for the administration of gene therapy, namely, syringes, scalpels, catheters, tubes for the administration of gene therapy products; surgical and medical apparatus and instruments for the administration of gene therapy products;

IMMSTAT

CHEMICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPOSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING NUCLEIC ACID FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER;IMMUNOSYSTEMS STAT;INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY, NAMELY, SYRINGES, SCALPELS, CATHETERS, TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS; SURGICAL AND MEDICAL APPARATUS AND INSTRUMENTS FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS;

IMMSTAT

Chemical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acids, viral vectors or non viral vectors for gene therapy; pharmaceutical preparations containing nucleic acids, viral vectors or non viral vectors for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, neurodegenerative disorders, diseases of the eye which result in vision impairment or loss, diseases of the ear which result in hearing impairment or loss, and bodily conditions associated with impaired immune systems; pharmaceutical preparations in the field of gene therapy; pharmaceutical preparations for the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, neurodegenerative disorders, diseases of the eye which result in vision impairment or loss, diseases of the ear which result in hearing impairment or loss, and bodily conditions associated with impaired immune systems;Instruments and apparatus for the administration of gene therapy products, namely, syringes, injectors, scalpels, catheters, indwelling catheters, pumps, tubes for the administration of gene therapy products; surgical instruments for the administration of gene therapy products;

INNUREX

In the heading, delete class 42. Statement(s): Column 2, line 2, after technologies in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease Column 2, line 4, after products in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease Column 2, line 13 after vascularisation in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease should be inserted.;Gene therapy and prophylaxis products, pharmaceutical substances and preparations for use in the medical industry, namely, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; vector production technologies and neurogenomics products in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; Chemical products for use in medical science for the treatment of diseases of the eye, vascular and neo-vascularisition disorders, single gene disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation *and injuries of the nervous, system all* in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; pharmaceutical and biochemical preparations for the treatment of damaged nerves and spinal injuries and for the induction of nerve re-growth; medical instruments and apparatus for the administration of gene and antibody-based therapy and prophylactics, preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes, all in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease;In the statement, Page 2, Column 1, line 15, after Vascularisation and injuries of the nervous, system, all should be inserted.;Chemical and biochemical products for use in gene delivery technology, enzymes and chemicals for in vitro use in laboratories and for analysis in gene delivery technology, enzymes and chemicals for in vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic variations thereof, all for in vivo use in gene delivery technology and catalysts for gene delivery technology in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease;

LENTISCREEN

GENE THERAPY AND PROPHYLAXIS PRODUCTS, NAMELY, GENE DELIVERY PRODUCTS; ENZYMES AND ENZYME PREPARATIONS FOR USE IN THE MEDICAL INDUSTRY, VECTORS, RETROVIRAL VECTORS AND VECTOR AND RETROVIRAL VECTOR MANUFACTURING PREPARATIONS, ALL FOR USE IN GENE DELIVERY TECHNOLOGY, PRODUCTS FOR USE IN VECTOR PRODUCTION TECHNOLOGIES, NEUROGENOMICS PRODUCTS; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR ASSISTANCE IN DELIVERING GENE THERAPY AND PROPHYLAXIS, NAMELY, GENE DELIVERY SYSTEMS; VACCINES FOR USE IN THE TREATMENT OF DISEASES OF THE BRAIN AND NERVOUS SYSTEM AND MOTOR NEURONE DISEASES, GENE THERAPY AND PROPHYLAXIS AND CHEMICALS AND BIOCHEMICALS FOR USE IN THE MEDICAL INDUSTRY;CHEMICAL AND BIOCHEMICAL PRODUCTS FOR USE IN THE GENE DELIVERY TECHNOLOGY, ENZYMES AND CHEMICALS FOR IN VITRO USE IN LABORATORIES AND FOR ANALYSIS FOR USE IN THE GENE DELIVERY TECHNOLOGY, MICRO-ORGANISMS, DEOXYRIBONUCLEIC ACID SEQUENCES, CLONING VEHICLES AND RECOMBINANT DEOXYRIBONUCLEIC ACID AND VARIATIONS THEREOF, ALL FOR IN VIVO USE IN GENE DELIVERY TECHNOLOGY, AND CATALYSTS FOR GENE DELIVERY TECHNOLOGY;SCIENTIFIC AND MEDICAL RESEARCH AND DEVELOPMENT, GENETIC ENGINEERING SERVICES, BIOTECHNOLOGY SERVICES, NAMELY, BIOTECHNOLOGY RESEARCH IN THE DEVELOPMENT OF THERAPEUTIC PRODUCTS AND VACCINES; MEDICAL RESEARCH AND DEVELOPMENT IN THE FIELD OF VECTOR PRODUCTION TECHNOLOGIES;

LENTITRAP

GENE THERAPY AND PROPHYLAXIS PRODUCTS, NAMELY, GENE DELIVERY PRODUCTS; ENZYMES AND ENZYME PREPARATIONS FOR USE IN THE MEDICAL INDUSTRY, VECTORS, RETROVIRAL VECTORS AND VECTOR AND RETROVIRAL VECTOR MANUFACTURING PREPARATIONS, ALL FOR USE IN GENE DELIVERY TECHNOLOGY, PRODUCTS FOR USE IN VECTOR PRODUCTION TECHNOLOGIES, NEUROGENOMICS PRODUCTS; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR ASSISTANCE IN DELIVERING GENE THERAPY AND PROPHYLAXIS, NAMELY, GENE DELIVERY SYSTEMS; VACCINES FOR USE IN THE TREATMENT OF DISEASES OF THE BRAIN AND NERVOUS SYSTEM AND MOTOR NEURONE DISEASES, GENE THERAPY AND PROPHYLAXIS AND CHEMICALS AND BIOCHEMICALS FOR USE IN THE MEDICAL INDUSTRY;CHEMICAL AND BIOCHEMICAL PRODUCTS FOR USE IN THE GENE DELIVERY TECHNOLOGY, ENZYMES AND CHEMICALS FOR IN VITRO USE IN LABORATORIES AND FOR ANALYSIS FOR USE IN THE GENE DELIVERY TECHNOLOGY, MICRO-ORGANISMS, DEOXYRIBONUCLEIC ACID SEQUENCES, CLONING VEHICLES AND RECOMBINANT DEOXYRIBONUCLEIC ACID AND VARIATIONS THEREOF, ALL FOR IN VIVO USE IN GENE DELIVERY TECHNOLOGY AND CATALYSTS FOR GENE DELIVERY TECHNOLOGY;SCIENTIFIC AND MEDICAL RESEARCH AND DEVELOPMENT, GENETIC ENGINEERING SERVICES, BIOTECHNOLOGY SERVICES, NAMELY, BIOTECHNOLOGY RESEARCH IN THE DEVELOPMENT OF THERAPEUTIC PRODUCTS AND VACCINES; MEDICAL RESEARCH AND DEVELOPMENT IN THE FIELD OF VECTOR PRODUCTION TECHNOLOGIES;

LENTIVECTOR

material treatment, namely, chemical synthesis for others featuring the development of a process to manufacture ingredients or finished biochemical products for applications in biotechnology;clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations containing nucleic acid for a system delivering genes to non-dividing cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, leukemia and bodily conditions associated with impaired immunosystem;chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations;scientific and medical research and development, medical services; genetic engineering services, biotechnology services, namely, research and development of new products in the field of biotechnology;

LENTIVECTOR

Material treatment, namely, chemical synthesis for others featuring the development of a process to manufacture ingredients or finished biochemical products for applications in biotechnology;Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations containing nucleic acid for a system delivering genes to non-dividing cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, leukemia and bodily conditions associated with impaired immunosystem;Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations;Medical services;Scientific and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new products in the field of biotechnology;

LENTIVECTOR

Clinical medical reagents for use in gene therapy; [ pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; ] retroviral vector preparations for use in gene therapy [ ; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS, neurodegenerative diseases, diseases of the eye, leukemia and bodily conditions associated with impaired immunosystems ];Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations;Scientific and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new products in the field of biotechnology;

METXIA

CLINICAL MEDICAL REAGENTS FOR USE IN GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR USE IN GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING LIPSOME REAGENTS SUITABLE FOR GENE THERAPY; THERAPEUTIC COMPOSITIONS CONTAINING NUCLEIC ACID FOR GENE THERAPY; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS, CANCER, HIV AND AIDS RELATED INFECTIONS AND BODILY CONDITIONS ASSOCIATED WITH IMPAIRED IMMUNOSYSTEMS; PHARMACEUTICAL PREPARATIONS IN THE FIELD OF GENE THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER;CHEMICAL COMPOSITIONS CONTAINING NUCLEIC ACIDS FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS AND RETROVIRAL VECTOR PREPARATIONS;INSTRUMENTS AND APPARATUS FOR THE ADMINISTRATION OF GENE THERAPY AND GENE THERAPY PRODUCTS, NAMELY, SYRINGES, SCALPELS, CATHETERS, AND TUBES FOR THE ADMINISTRATION OF GENE THERAPY PRODUCTS;

MONUDIN

Gene therapy and prophylaxis products, namely gene transfer, regulation, modulation and delivery products for the treatment of motor neurone disease, blood disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, vascular disorders, disorders arising from improper vascularization and single gene disorders; pharmaceutical substances and preparations namely, vaccines, genetically engineered proteins enzymes and enzyme preparations for medical diagnostic use; retroviral vector and retroviral vector manufacturing preparations for use in gene delivery; pharmaceutical and biochemical preparations for the treatment of single gene disorders;Chemical and biochemical products for use in gene delivery technology, namely, enzymes, proteins, growth factors and chemicals for in-vitro use in laboratories and for analysis in gene delivery technology; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology;Instruments and apparatus for the administration of gene and antibody-based therapy and prophylaxis preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes, all for the treatment of single gene disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, blood disorders, vascular disorders and disorders arising from inappropriate vascularization;Scientific and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new technology for others in the field of biotechnology; licensing of intellectual property; product development consultation relating to gene therapy products; consultation services in the fields of medical and scientific research in the field of professional gene therapy;

OXB SOLUTIONS

Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; biotechnology contract manufacturing services; contract manufacturing of viral and non-viral vectors; manufacture of vaccines;Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceuticals in the form of nanoparticles for delivery; pharmaceutical substances and preparations; pharmaceutical substances and preparations, nanoparticals, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vector, retroviral vector, lentiviral vector and non-viral vector manufacturing preparations; biochemical and chemical products for use in medical science; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes;Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing and management of intellectual property; consultancy, advice and information in the field of drug regulatory approval; regulatory advice relating to chemistry manufacturing and controls (CMC) activities;Medical diagnostic services; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; preparation of medical reports; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals;Research and laboratory analytic, diagnostic, biochemistry and genetic engineering services; design of manufacturing facilities; quality control and validation services; Product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; laboratory services; scientific and technological services and research; industrial analysis services; provision of scientific information; research and scientific analysis relating to drug discovery and development for others; conducting clinical trials; manufacturing and manufacturing development services;

OXFORD BIOMEDICA

Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders;OXFORD BIO MEDICAL;Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use;Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives;Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, medical syringes and injectors for medical purposes;OXFORD;Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials;

OXFORD BIOMEDICA SOLUTIONS

Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; biotechnology contract manufacturing services; contract manufacturing of viral and non-viral vectors; manufacture of vaccines;Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceuticals in the form of nanoparticles for delivery; pharmaceutical substances and preparations; pharmaceutical substances and preparations, nanoparticals, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vector, retroviral vector, lentiviral vector and non-viral vector manufacturing preparations; biochemical and chemical products for use in medical science; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes;Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing and management of intellectual property; consultancy, advice and information in the field of drug regulatory approval; regulatory advice relating to chemistry manufacturing and controls (CMC) activities;Medical diagnostic services; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; preparation of medical reports; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals;Research and laboratory analytic, diagnostic, biochemistry and genetic engineering services; design of manufacturing facilities; quality control and validation services; Product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; laboratory services; scientific and technological services and research; industrial analysis services; provision of scientific information; research and scientific analysis relating to drug discovery and development for others; conducting clinical trials; manufacturing and manufacturing development services;

PLENTI

clinical medical reagents for use in gene therapy, pharmaceutical preparations for use in gene therapy,enzymes and enzyme preparations for medical purpose, for use in gene delivery and cloning technology, retroviral vector and retroviral vector manufacturing preparations for use in gene delivery and cloning technology;chemicals for use in the manufacture of viruses, vectors, pharmaceuticals and retroviral vector preparations for use in industry, science and medical science; enzymes and chemical products for in vitro use in laboratories and for analysis in and development of gene delivery technology; micro organisms, cell cultures, plasmids and cultures of micro organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid and variations thereof, all for in vivo or ex vivo use in gene delivery technology and cloning technology;Medical Services;scientific and medical research and development, and product development; genetic engineering services, biotechnology services, namely research and development of new products for others in the field of gene technology and gene therapy;

PLENTIVECTOR

Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations containing nucleic acid for a system delivering genes to non-dividing cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS related infections, leukemia and bodily conditions associated with impaired immunosystem;Chemical compositions containing nucleic acids for use in the manufacture of pharmaceutical and retroviral vector preparations;medical services;Scientific and medical product research and development, genetic engineering services for scientific and medical research use, biotechnology services, namely, research and development of new products in the field of biotechnology, genetic engineering services for scientific and medical research use;

PONY

clinical medical reagents for use in gene therapy, pharmaceutical preparations for use in gene therapy, enzymes and enzyme preparations for medical purpose, for use in gene delivery and cloning technology, retroviral vector and retroviral vector manufacturing preparations for use in gene delivery and cloning technology, none of the aforesaid goods relating to the treatment of equidae;chemicals for use in the manufacture of viruses, vectors, pharmaceuticals and retroviral vector preparations for use in industry, science and medical science; enzymes and chemical products for in vitro use in laboratories and for analysis in and development of gene delivery technology; micro organisms, cell cultures, plasmids and cultures of micro organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid and variations thereof, all for in vivo or ex vivo use in gene delivery technology and cloning technology, none of the aforesaid goods relating to the treatment of equidae;medical services;scientific and medical research and development, and product development; genetic engineering services, biotechnology services, namely research and development of new products for others in the field of gene technology and gene therapy, none of the aforesaid services relating to the treatment of equidae;

PROCASTAT

clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations of the treatment of prostate cancer; pharmaceutical preparations containing nucleic acid for use in the treatment of prostate cancer;instruments and apparatus for the administration of gene therapy, namely, syringes, scalpels, catheters and tubes, for medical services surgical and medical apparatus and instruments, namely, syringes, scalpels, catheters, tubes for medical services;

PROCASTAT

Clinical medical reagents for use in gene therapy; pharmaceutical preparations, namely, vaccines for use in gene therapy; therapeutic compositions containing liposome reagents or nucleic acid suitable for gene therapy for use in the treatment of cancer and auto-immune disorders; pharmaceutical preparations containing nucleic acids for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS-related infections and bodily conditions associated with impaired immunosystems, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularization diseases of the nervous system, cardiac disorders, inflammatory and auto-immune diseases; pharmaceutical preparations and vaccines for use in the treatment of cancer, single gene disorders, hemophilia, blood disorders, vascular disorders and disorders arising from inappropriate vascularization, diseases of the nervous system, cardiac disorders, inflammatory and auto-immune diseases; enzymes and enzymatic preparations for medical use in the treatment of bacterial infections; retroviral vector preparations for medical use in the treatment of cancer; and chemotherapeutics for medical use;Instruments and apparatus for the administration of gene therapy products, namely, vials, syringes, injectors, catheters and tubes; and surgical and medical apparatus and instruments, namely, scalpels, knives, forceps and surgical clips;

PROCASTAT

Gene therapy products, namely, pharmaceutical preparation vectors for use in gene therapy, clinical medical reagents, therapeutic compositions containing vectors for gene therapy for use in the treatment of cancer, neurological, ocular, hearing, balance and auto-immune disorders; enzymes and enzyme preparations for gene therapy purposes, retroviral vector and retroviral vector manufacturing preparations, all for the field of gene therapy, for the treatment of prostate cancer;Instruments and apparatus for the administration of gene therapy products; surgical and medical apparatus and instruments;

PROCASTAT

Gene therapy products, namely, pharmaceutical preparation vectors for use in gene therapy, clinical medical reagents, therapeutic compositions containing vectors for gene therapy for use in the treatment of cancer, neurological, ocular, hearing, balance and auto-immune disorders; Enzymes and enzyme preparations for gene therapy purposes, retro viral vector and retro viral vector manufacturing preparations, all for the field of gene therapy, for the treatment of prostate cancer, with the exclusion of products intended for the treatment of cardiovascular diseases;Color is not claimed as a feature of the mark.;Instruments and apparatus for the administration of gene therapy products, namely, vials, syringes, injectors, pumps, catheters, indwelling catheters and tubes; and surgical and medical apparatus and instruments, namely, scalpels, knives, forceps and surgical clips; surgical instruments;

PROSAVIN

clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapeutic compositions containing nucleic acid for gene therapy; pharmaceutical preparations of the treatment of prostate cancer; pharmaceutical preparations containing nucluic acid for use in the treatment of prostate cancer;instruments and apparatus for the administration of gene therapy, namely, syringes, scalpels, catheters and tubes, for medical services surgical and medical apparatus and instruments, namely, syringes, scalpels, catheters, tubes for medical services;

PROSAVIN

Gene therapy products, namely, gene-based medicines and injectable pharmaceuticals for the treatment of neuro-degenerative disorders;enzymes and enzyme preparations for medical purposes, namely, for the treatment of neuro-degenerative disorders; retroviral vector preparations and manufacture of retroviral vector preparations, all for use in gene-based medicines and injectable pharmaceuticals for the treatment of neuro-degenerative disorders; chemical products for in vitro diagnosis for medical use, excluding products for veterinary purposes;Instruments and apparatus for the administration of gene therapy, namely, injection devices, syringes, scalpels, catheters and tubes for medical services; surgical and medical apparatus and instruments, namely, injection devices, syringes, scalpels, catheters, tubes for medical services, excluding products for veterinary purposes;

REPOXYGEN

Gene therapy and prophylaxis products, pharmaceutical substances and preparations, and chemical products for use in medical science, all for haematological disorders; vaccines, enzymes and enzyme preparations, pharmaceuticals for the delivery of erythropoietin genes to muscle cells, all for medical purposes; hypoxia response pharmaceutical substances and preparations, viral and retroviral vectors, viral and retroviral vector manufacturing preparations; pharmaceutical and biochemical preparations for the treatment of anaemia;REP OXYGEN;Chemical products for use in industry and science; enzymes; chemical products for in-vitro use in laboratories and for analysis; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles, namely chemical products for use in biotechnology, research and development and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use;Instruments and apparatus for the administration of gene therapy and prophylaxis preparations and substances, pre-filled vials; syringes and injectors for medical purposes;Scientific and medical research and development; genetic engineering services, biotechnology services, licensing of intellectual property, advisory services relating to gene therapy products;

REQUINATE

Gene therapy and prophylaxis products, namely, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of hemophilia, blood disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, vascular disorders, disorders arising from improper vascularization and single gene disorders; pharmaceutical substances and preparations namely, vaccines, genetically engineered proteins enzymes and enzyme preparations for medical diagnostic use; retroviral vector and retroviral vector manufacturing preparations for use in gene delivery; pharmaceutical and biochemical preparations for the treatment of single gene disorders;Chemical and biochemical products for use in gene delivery technology, namely, enzymes, proteins, growth factors and chemicals for in-vitro use in laboratories and for analysis in gene delivery technology; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology;Instruments and apparatus for the administration of antibody-based therapy and prophylaxis preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes, all for the treatment of single gene disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, blood disorders, vascular disorders and disorders arising from inappropriate vascularization;Scientific and medical research and development; engineering services; biotechnology services, namely, research for others in the field of biotechnology, biotechnology research in the development of therapeutic and prophylactic products and vaccines; licensing of intellectual property; advisory services relating to the research and development of gene therapy and prophylaxis products; consultation services in the field of medical and scientific research in the field of professional gene therapy; medical research and development in the field of vector production technologies;

RETINOSTAT

Gene therapy and prophylaxis products, namely, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of [ blood disorders, cancers, diseases of the nervous system, ] macular degeneration, diabetic retinopathy, [ diabetes, inflammatory and auto-immune diseases, vascular disorders, ] disorders arising from improper vascularisation and single gene disorders; pharmaceutical substances and preparations for use in the medical industry, namely, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies, vector production technologies and neurogenomics products; chemical products for use in medical science, particularly for treatment of disease of the eye, vascular and neovascularisation disorders and retinopathy; pharmaceutical and biochemical preparations for the treatment of macular degeneration and retinopathy [ and angiogenesis; ] instruments and apparatus for the administration of gene and [ antibody-based ] therapy and prophylaxis preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes;Color is not claimed as a feature of the mark.;Chemical and biochemical products for use in gene delivery technology, namely, enzymes; chemical products for in-vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology;Scientific and medical research and development; [ engineering services, biotechnology services, namely, biotechnology research in the development of therapeutic and prophylactic products and vaccines; licensing of intellectual property; ] advisory services relating to the research and development of gene therapy; consultation services in the fields of medical and scientific research in the field of professional gene therapy [; medical research and development in the field of vector production technologies ];

SMARTOMICS

GENE THERAPY AND PROPHYLAXIS PRODUCTS, NAMELY, GENE DELIVERY PRODUCTS; ENZYMES AND ENZYME PREPARATIONS FOR USE IN THE MEDICAL INDUSTRY, VECTORS, RETROVIRAL VECTORS, VECTOR AND RETROVIRAL VECTOR MANUFACTURING PREPARATIONS, ALL FOR USE IN GENE DELIVERY TECHNOLOGY, PRODUCTS FOR USE IN VECTOR PRODUCTION TECHNOLOGIES, NEUROGENOMICS PRODUCTS; PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS FOR ASSISTANCE IN DELIVERING GENE THERAPY AND PROPHYLAXIS, NAMELY, GENE DELIVERY SYSTEMS; VACCINES FOR USE IN THE TREATMENT OF DISEASES OF THE BRAIN AND NERVOUS SYSTEM AND MOTOR NEURONE DISEASES, GENE THERAPY AND PROPHYLAXIS AND CHEMICALS AND BIOCHEMICALS FOR USE IN THE MEDICAL INDUSTRY;CHEMICAL AND BIOCHEMICAL PRODUCTS FOR USE IN THE GENE DELIVERY TECHNOLOGY, ENZYMES AND CHEMICALS FOR IN VITRO USE IN LABORATORIES AND FOR ANALYSIS FOR USE IN THE GENE DELIVERY TECHNOLOGY, MICRO-ORGANISMS, DEOXYRIBONUCLEIC ACID SEQUENCES, CLONING VEHICLES AND RECOMBINANT DEOXYRIBONUCLEIC ACID AND VARIATIONS THEREOF, ALL FOR IN VIVO USE IN GENE DELIVERY TECHNOLOGY AND CATALYSTS FOR GENE DELIVERY TECHNOLOGY;SCIENTIFIC AND MEDICAL RESEARCH AND DEVELOPMENT, GENETIC ENGINEERING SERVICES, BIOTECHNOLOGY SERVICES, NAMELY, BIOTECHNOLOGY RESEARCH IN THE DEVELOPMENT OF THERAPEUTIC PRODUCTS AND VACCINES; MEDICAL RESEARCH AND DEVELOPMENT IN THE FIELD OF VECTOR PRODUCTION TECHNOLOGIES;

STARGEN

Gene therapy and prophylaxis products, namely, proteins, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic and angiogenic molecules, all for the treatment of degenerative diseases of the eyes, including Stargardt disease and other degenerative diseases of the eyes; pharmaceutical preparations for treatment of degenerative diseases of the eyes, including Stargardt disease and other degenerative diseases of the eye; retroviral vector and retroviral vector manufacturing preparations, namely, pharmaceutical and biochemical preparations for the treatment of degenerative diseases of the eyes, including Stargardt disease and other degenerative retinal diseases; gene based pharmaceutical preparations for the treatment of degenerative diseases of the eyes;STAR GEN;Licensing of intellectual property in respect of gene therapy products;Scientific and medical research and development in respect of diseases of the eye; genetic engineering services; biotechnology services, relating to gene therapy products, namely, development of new technology for others in the field of biotechnology and medical research, namely, development of new technologies for others for diagnosis and treatment of diseases of the eyes;

TRIST

Gene therapy and prophylaxis products, namely, gene delivery pharmaceuticals; pharmaceuticals for the delivery of genes to muscle cells, all for medical purposes; vaccines, enzymes, and enzyme preparations for the treatment of cancer; hypoxia response pharmaceutical substances and preparations, viral and retroviral vectors, viral and retroviral vector manufacturing preparations for the treatment of cancer; pharmaceutical and biochemical preparations for the treatment of cancer;Chemicals for use in industry and science, namely, enzymes for scientific and research purposes; chemical products for in-vitro use in laboratories and for analysis, namely, enzymes and chemicals for use in gene delivery technology for laboratory and research use; micro-organisms for laboratory and research use, cell cultures for laboratory and research use, plasmids and cultures of micro organisms for laboratory and research use, deoxyribonucleic acid sequences for laboratory and research use, cloning vehicles, namely, chemical preparations for scientific purposes for use in biotechnology, research and development and recombinant deoxyribonucleic acid variations thereof for laboratory and research use, all for in-vivo use;Instruments and apparatus for the administration of gene therapy vaccines and prophylaxis preparations and substances and pre-filled vials, syringes and injectors containing pharmaceuticals for the treatment of cancer sold as a unit;Scientific and medical research and development; genetic engineering services for scientific purposes; biotechnology services, namely, research and development in the field of biotechnology and providing information on the subject of scientific research in the field of biotechnology; scientific advisory services relating to gene therapy products and clinical trials, conducting clinical trials;

TROVAX-VET

Pharmaceutical and veterinary preparations for the treatment of cancer, auto-immune diseases, diseases of the nervous system, inflammatory diseases, vascular disorders and disorders arising from improper vascularisation; gene therapy and prophylaxis products for the veterinary treatment of cancer, namely, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations; vaccines, gene therapy, prophylaxis vector and vector manufacturing preparations for the treatment of cancer in animals and humans;TROVAX VETERINARY;Instruments and apparatus for the administration of vaccines, namely, syringes and injectors; gene therapy and prophylaxis products, namely; syringes and injectors; surgical and medical apparatus and instruments for gene therapy and prophylaxis, pre-filled syringes, vials and injectors for medical purposes for animals and humans;Scientific and medical research and development for new products for animals and humans; genetic engineering services, namely, providing scientific researches for others in the fields of genetic engineering; biotechnology services, namely, providing research in the development of therapeutic and prophylactic products and vaccines;

USHSTAT

In the statement, page 2, line 6, 4-12-2009, is deleted and 12-4-2009, should be inserted.;Gene therapy products, namely, genetically engineered tissues for transplant purposes and gene delivery pharmaceuticals; vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, all for medical purposes; nucleic acid sequences and chemical reagents for medical purposes, namely, retroviral vectors and retroviral vector manufacturing preparations; pharmaceutical and biochemical preparations for the treatment of diseases of the eye and Usher's disease; biochemical preparations for medical purposes, namely, gene based therapeutics for the treatment of a juvenile degenerative retinal disease; pre-filled vials containing gene therapy pharmaceutical preparations;Enzymes for scientific and research purposes; chemicals for use in industry and science, namely, chemicals for in-vitro use and analysis in laboratories; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, nucleic acid sequences and chemical reagents for other than medical and veterinary purposes, namely, cloning vehicles and vectors and recombinant deoxyribonucleic acid variations thereof, all for in-vitro and in-vivo use in laboratory or medical research; chemical reagents for use in medical science;Medical instruments and apparatus for the administration of antibody-based therapy, gene therapy and prophylaxis preparations and substances; syringes and injectors for medical purposes;Scientific and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new products for others in the field of biotechnology; advisory services relating to research and development of gene therapy products;

USHSTAT

Gene therapy products, namely, genetically engineered tissues for transplant purposes and gene delivery pharmaceuticals; vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, all for medical purposes; nucleic acid sequences and chemical reagents for medical purposes, namely, retroviral vectors and retroviral vector manufacturing preparations; pharmaceutical and biochemical preparations for the treatment of diseases of the eye and Usher's disease; biochemical preparations for medical purposes, namely, gene based therapeutics for the treatment of a juvenile degenerative retinal disease; pre-filled vials containing gene therapy pharmaceutical preparations;Enzymes for scientific and research purposes; chemicals for use in industry and science, namely, chemicals for in-vitro use and analysis in laboratories; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, nucleic acid sequences and chemical reagents for other than medical and veterinary purposes, namely, cloning vehicles and vectors and recombinant deoxyribonucleic acid variations thereof, all for in-vitro and in-vivo use in laboratory or medical research; chemical reagents for use in medical science;Medical instruments and apparatus for the administration of antibody-based therapy, gene therapy and prophylaxis preparations and substances; syringes and injectors for medical purposes;Scientific and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new products for others in the field of biotechnology; advisory services relating to research and development of gene therapy products;